Legal & General Group Plc lowered its stake in shares of Flexion Therapeutics, Inc. (NASDAQ:FLXN) by 1.3% during the first quarter, Holdings Channel reports. The firm owned 6,725 shares of the specialty pharmaceutical company’s stock after selling 86 shares during the period. Legal & General Group Plc’s holdings in Flexion Therapeutics were worth $181,000 at the end of the most recent reporting period.

Other institutional investors have also added to or reduced their stakes in the company. Royce & Associates LP acquired a new position in Flexion Therapeutics during the first quarter valued at $1,346,000. Teachers Advisors LLC raised its stake in shares of Flexion Therapeutics by 3.1% in the first quarter. Teachers Advisors LLC now owns 44,796 shares of the specialty pharmaceutical company’s stock worth $1,205,000 after buying an additional 1,328 shares in the last quarter. Asset Management One Co. Ltd. purchased a new stake in shares of Flexion Therapeutics during the first quarter worth about $319,000. American International Group Inc. raised its stake in shares of Flexion Therapeutics by 52.3% in the first quarter. American International Group Inc. now owns 16,212 shares of the specialty pharmaceutical company’s stock worth $436,000 after buying an additional 5,569 shares in the last quarter. Finally, EAM Investors LLC raised its stake in shares of Flexion Therapeutics by 259.5% in the first quarter. EAM Investors LLC now owns 132,595 shares of the specialty pharmaceutical company’s stock worth $3,568,000 after buying an additional 95,713 shares in the last quarter. Institutional investors and hedge funds own 75.43% of the company’s stock.

Shares of Flexion Therapeutics, Inc. (NASDAQ:FLXN) traded up 4.39% during midday trading on Friday, reaching $22.83. The company had a trading volume of 284,919 shares. The stock’s 50 day moving average is $22.55 and its 200-day moving average is $21.25. The stock’s market capitalization is $728.39 million. Flexion Therapeutics, Inc. has a 12-month low of $15.44 and a 12-month high of $29.41.

Flexion Therapeutics (NASDAQ:FLXN) last posted its quarterly earnings results on Tuesday, August 8th. The specialty pharmaceutical company reported ($0.91) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.80) by $0.11. On average, equities research analysts predict that Flexion Therapeutics, Inc. will post ($3.67) earnings per share for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: “Flexion Therapeutics, Inc. (NASDAQ:FLXN) Position Decreased by Legal & General Group Plc” was first reported by Daily Political and is the sole property of of Daily Political. If you are reading this story on another publication, it was copied illegally and reposted in violation of U.S. and international trademark and copyright law. The original version of this story can be read at https://www.dailypolitical.com/2017/08/13/flexion-therapeutics-inc-nasdaqflxn-position-decreased-by-legal-general-group-plc.html.

A number of equities research analysts recently issued reports on the company. Cantor Fitzgerald reissued a “buy” rating and issued a $34.00 target price on shares of Flexion Therapeutics in a research report on Wednesday, April 26th. Zacks Investment Research lowered Flexion Therapeutics from a “hold” rating to a “sell” rating in a research report on Thursday, July 13th. Janney Montgomery Scott reissued a “buy” rating and issued a $35.00 target price (up previously from $30.00) on shares of Flexion Therapeutics in a research report on Wednesday, July 12th. BMO Capital Markets reissued a “buy” rating on shares of Flexion Therapeutics in a research report on Friday. Finally, Royal Bank Of Canada reissued a “buy” rating and issued a $44.00 target price on shares of Flexion Therapeutics in a research report on Friday, July 7th. One investment analyst has rated the stock with a sell rating, one has given a hold rating, seven have given a buy rating and one has issued a strong buy rating to the company’s stock. Flexion Therapeutics presently has an average rating of “Buy” and a consensus target price of $31.30.

In related news, insider Michael D. Clayman purchased 5,000 shares of the business’s stock in a transaction dated Monday, June 5th. The stock was purchased at an average cost of $17.23 per share, with a total value of $86,150.00. Following the completion of the acquisition, the insider now directly owns 20,146 shares of the company’s stock, valued at $347,115.58. The purchase was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Mark Stejbach purchased 1,580 shares of the business’s stock in a transaction dated Friday, June 16th. The stock was bought at an average cost of $17.02 per share, with a total value of $26,891.60. The disclosure for this purchase can be found here. 15.98% of the stock is owned by company insiders.

About Flexion Therapeutics

Flexion Therapeutics, Inc is a United States-based specialty pharmaceutical company. The Company is focused on the development and commercialization of local therapies for the treatment of patients with musculoskeletal conditions, beginning with osteoarthritis (OA), a type of degenerative arthritis. The Company’s lead product candidate, Zilretta, is a late-stage, injectable, extended-release, intra-articular (IA) investigational steroid.

Want to see what other hedge funds are holding FLXN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Flexion Therapeutics, Inc. (NASDAQ:FLXN).

Institutional Ownership by Quarter for Flexion Therapeutics (NASDAQ:FLXN)

Receive News & Ratings for Flexion Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Flexion Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.